Clinical relevance of genetic heterogeneity in HCV

Future Virology

Volumn 5, Issue 1, 2010, Pages 33-49

  González Candelas, Fernando ^a   López Labrador, F Xavier ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Genomics and Health   (Spain)

Author keywords

Genetic variability; HCV genotypes; HCV subtypes; Hypervariable regions; Immune response; Interferon; Nonstructural regions; Positive selection; Purifying selection; Ribavirin; STAT C

Indexed keywords

ALPHA2A INTERFERON; BOCEPREVIR; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; HLA ANTIGEN; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; RETINOIC ACID INDUCIBLE PROTEIN I; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; STRUCTURAL PROTEIN; TELAPREVIR; VIRUS RNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANTIGEN PRESENTATION; ANTIVIRAL RESISTANCE; CLINICAL PRACTICE; DISEASE COURSE; DRUG DESIGN; GENETIC CONSERVATION; GENETIC DRIFT; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MEDICAL RESEARCH; NATURAL SELECTION; PHARMACOGENETICS; POPULATION GENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RNA STRUCTURE; RNA VIRUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS TRANSMISSION;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 74049104116     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.63     Document Type: Review

References (134)

1. Wasley A, Alter MJ: Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20, 1-16 (2000).
2. Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567 (2005).
3. Abdel-Aziz F, Habib M, Mohamed MK et al.: Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 32, 111-115 (2000).
4. Hoofnagle JH: Course and outcome of hepatitis C. Hepatology 36, S21-S29 (2002).
5. Berenguer M, Lopez-Labrador FX, Wright TL: Hepatitis C and liver transplantation. J. Hepatol. 35, 666-678 (2001).
6. Dubuisson J: Hepatitis C virus proteins. World J. Gastroenterol. 13, 2406-2415 (2007).
7. + T-cell epitopes - a large-scale immunomic analysis. Bioinformatics 25(12), i39-i44 (2009).
8. Kimura M: Evolutionary rate at the molecular level. Nature 217, 624-626 (1968).
9. Kimura M: The Neutral Theory of Molecular Evolution. Cambridge University Press, Cambridge, UK (1983).
10. Ohta T, Kimura M: On the constancy of the evolutionary rate of cistrons. J. Mol. Evol. 1, 18-25 (1971).
11. Ohta T: The nearly neutral theory of molecular evolution. Ann. Rev. Ecol. Syst. 21, 263-286 (1992).
12. Leigh Brown AJ: Analysis of HIV-1 env gene sequences reveal evidence for a low effective number in the viral population. Proc. Natl Acad. Sci. USA 94, 1862-1865 (1997).
13. Shriner D, Shankarappa R, Jensen MA et al.: Influence of random genetic drift on human immunodeficiency virus type 1 env evolution during chronic infection. Genetics 166, 1155-1164 (2004).
14. Duffy S, Shackelton LA, Holmes EC: Rates of evolutionary change in viruses: patterns and determinants. Nat. Rev. Genet. 9, 267-276 (2008). ■■ Review and analysis of factors determining viral rates of evolution, which extend beyond high mutation rates due to lack of proofreading polymerases.
15. Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R: Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83, 5760-5764 (2009). ■ New methodology for the estimation of mutation rates in viral populations is proposed and applied to HCV before and after interferon/ribavirin treatment.
16. Belshaw R, Gardner A, Rambaut A, Pybus OG: Pacing a small cage: mutation and RNA viruses. Trends Ecol. Evol. 23, 188-193 (2008).
17. Drake JW, Holland JJ: Mutation rates among RNA viruses. Proc. Natl Acad. Sci. USA 96,13910-13913 (1999).
18. Neumann AU, Lam NP, Dahari H et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103-107 (1998).
19. Simmonds P, Tuplin A, Evans DJ: Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: implications for virus evolution and host persistence. RNA 10, 1337-1351 (2004).
20. Davis M, Sagan SM, Pezacki JP, Evans DJ, Simmonds P: Bioinformatic and physical characterizations of genome-scale ordered RNA structure in mammalian RNA viruses. J. Virol. 82, 11824-11836 (2008).
21. Yun Z, Lara C, Johansson B, Lorenzana de Rivera I, Sonnerborg A: Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J. Med. Virol. 49, 155-160 (1996).
22. Smith DB, Pathirana S, Davidson F et al.: The origin of hepatitis C virus genotypes. J. Gen. Virol. 78, 321-328 (1997).
23. Simmonds P, Smith DB, McOmish F et al.: Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J. Gen. Virol. 75, 1053-1061 (1994).
24. Viazov S, Widell A, Nordenfelt E: Mixed infection with two types of hepatitis C virus is probably a rare event. Infection 28, 21-25 (2000).
25. Kalinina O, Norder H, Mukomolov S, Magnius LO: A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J. Virol. 76, 4034-4043 (2002).
26. Kalinina O, Norder H, Magnius LO: Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. J. Gen. Virol. 85, 1853-1857 (2004).
27. Colina R, Casane D, Vasquez S et al.: Evidence of intratypic recombination in natural populations of hepatitis C virus. J. Gen. Virol. 85, 31-37 (2004).
28. Kageyama S, Agdamag DM, Alesna ET et al.: A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. J. Med. Virol. 78, 1423-1428 (2006).
29. Legrand-Abravanel F, Claudinon J, Nicot F et al.: A new natural intergenotypic (2/5) recombinant of hepatitis C virus. J. Virol. 81, 4357-4362 (2007).
30. Sentandreu V, Jiménez-Hernández N, Torres-Puente M et al.: Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS ONE 3, e3239 (2008).
31. Kurbanov F, Tanaka Y, Avazova D et al.: Detection of hepatitis C virus natural recombinant RF1-2k/1b strain among intravenous drug users in Uzbekistan. Hepatol. Res. 38, 457-464 (2008).
32. Weir BS: Genetic Data Analysis II: Methods for Discrete Population Genetic Data. Sinauer, Sunderland, MA, USA (1996).
33. Excoffier L, Smouse PE, Quattro JM: Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. Genetics 131, 479-491 (1992).
34. Simmonds P, Bukh J, Combet C et al.: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962-973 (2005).
35. Simmonds P: Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 85, 3173-3188 (2004).
36. Domingo E, Holland J, Biebricher C, Eigen M. Quasispecies: the concept and the word. In: Molecular Evolution of Viruses. Gibbs A (Ed.). Cambridge University Press, Cambridge, UK (1992). ■■ One of the basic references for understanding the concept of quasispecies applied to viral populations.
37. Holmes EC, Moya A: Is the quasispecies concept relevant to RNA viruses? J. Virol. 76, 460-462 (2002).
38. Eigen M: On the nature of virus quasispecies. Trends Microbiol. 4, 216-218 (1996).
39. Shirai M, Arichi T, Chen M et al.: T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region. J. Immunol. 162, 568-576 (1999).
40. Yagnik AT, Lahm A, Meola A, Roccasecca RM, Ercole BB, Nicosia A: A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40, 355-366 (2000).
41. Troesch M, Meunier I, Lapierre P et al.: Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352, 357-367 (2006).
42. Torres-Puente M, Cuevas JM, Jiménez N et al.: Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus. Infect. Genet. Evol. 8, 74-82 (2008).
43. Dustin LB, Rice CM: Flying under the radar: The immunobiology of hepatitis C. Annu. Rev. Immunol. 25, 71-99 (2007).
44. Pawlotsky JM: Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 299, 261-284 (2006). ■ Reviews the role for HCV and quasispecies variability and dynamics in acute and chronic infection and derived clinical implications.
45. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P: Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol. 50, 1142-1154 (2009).
46. Lopez-Labrador FX, Ampurdanes S, Forns X et al.: Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J. Hepatol. 27, 959-965 (1997).
47. Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM: The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J. Viral Hep. 16, 492-499 (2009).
48. Gigou M, Roque-Afonso AM, Falissard B, Penin F, Dussaix E, Feray C: Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J. Virol. 75, 11292-11297 (2001).
49. Lopez-Labrador FX, Berenguer M, Sempere A et al.: Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. Liver Transpl. 10, 217-227 (2004).
50. López-Labrador FX, Bracho A, Berenguer M et al.: Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation. J. Viral Hep. 13, 104-115 (2006).
51. Draenert R, Le Gall S, Pfafferott KJ et al.: Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J. Exp. Med. 199, 905-915 (2004).
52. Tester I, Smyk-Pearson S, Wang P et al.: Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J. Exp. Med. 201, 1725-1731 (2005).
53. +-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J. Virol. 76, 6104-6113 (2002).
54. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13, 46-53 (2007).
55. Neumann-Haefelin C, Frick DN, Wang JJ et al.: Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J. Virol. 82, 3438-3451 (2008).
56. Matthews PC, Leslie AJ, Katzourakis A et al.: HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering. J. Virol. 83, 4605-4615 (2009).
57. Crawford H, Prado JG, Leslie A et al.: Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J. Virol. 81, 8346-8351 (2007).
58. Poon AFY, Kosakovsky Pond SL, Bennett P, Richman DD, Leigh Brown AJ, Frost SDW: Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus. PLoS Pathog. 3, e45 (2007).
59. Helle F, Dubuisson J: Hepatitis C virus entry into host cells. Cell. Mol. Life Sci. 65, 100-112 (2008).
60. Ploss A, Evans MJ, Gaysinskaya VA et al.: Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882-886 (2009).
61. Blackard JT, Kemmer N, Sherman KE: Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 44, 15-22 (2006).
62. Fishman S, Murray J, Eng F, Walewski J, Morgello S, Branch A: Molecular and bioinformatic evidence of Hepatitis C virus evolution in brain. J. Infect. Dis. 197, 597-607 (2008).
63. Weissenborn K, Tryc A, Heeren M et al.: Hepatitis C virus infection and the brain. Metab. Brain Dis. 24, 197-210 (2009).
64. Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Ann. Rev. Pathol. Mech. Dis. 1, 23-61 (2006). ■■ Reviews the pathogenic mechanisms implicated in hepatitis B and C chronic infections, discussing similarities, differences and the key role of immunomediated damage.
65. Manns MP, Wedemeyer H, Cornberg M: Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350-1359 (2006).
66. Gluud LL, Marchesini E, Iorio A: PEGinterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. Am. J. Gastroenterol. 104(9), 2335-2341 (2009).
67. Enomoto N, Sakuma I, Asahina Y et al.: Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest 96, 224-230 (1995).
68. Germanidis G, Metallidis S, Lazaraki G, Pawlotsky JM, Nikolaidis P: NS5A sequences of hepatitis C virus genotype 1 and interferon resistance: where are we? J. Infect. Dis. 198, 154-155 (2008).
69. Saiz JC, Lopez-Labrador FX, Ampurdanes S et al.: The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J. Infect. Dis. 177, 839-847 (1998).
70. Sarrazin C, Berg T, Lee JH et al.: Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J. Hepatol. 30, 1004-1013 (1999).
71. Puig-Basagoiti F, Saiz JC, Forns X et al.: Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J. Med. Virol. 65, 35-44 (2001).
72. Dal Pero F, Tang KH, Gerotto M et al.: Impact of NS5A sequences of hepatitis C virus genotype 1a on early viral kinetics during treatment with PEGinterferon-a2a plus ribavirin. J. Infect. Dis. 196, 998-1005 (2007).
73. Torres-Puente M, Cuevas JM, Jiménez N et al.: Genetic variability in hepatitis C virus and its role in antiviral treatment response. J. Viral Hepat. 15, 188-199 (2008).
74. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C: Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 30, 1045-1053 (1999).
75. Gale M, Foy EM: Evasion of intracellular host defence by hepatitis C virus. Nature 436, 939-945 (2005).
76. Witherell GW, Beineke P: Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J. Med. Virol. 63, 8-16 (2001).
77. Pascu M, Martus P, Hohne M et al.: Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53, 1345-1351 (2004).
78. Schinkel J, Spaan WJ, Kroes AC: Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antivir. Ther. 9, 275-286 (2004).
79. Mori N, Imamura M, Kawakami Y et al.: Randomized trial of high-dose interferon-α-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J. Med. Virol. 81, 640-649 (2009).
80. Okanoue T, Itoh Y, Hashimoto H et al.: Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multicenter study. J. Gastroenterol. 44, 952-963 (2009).
81. Pawlotsky JM, Chevaliez S, McHutchison JG: The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132, 1979-1998 (2007).
82. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C et al.: Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J. Gastroenterol. 13, 2416-2426 (2007).
83. Schinkel J, de Jong MD, Bruning B, van Hoek B, Spaan WJ, Kroes AC: The potentiating effect of ribavirin on interferon in the treatment of hepatitis C: lack of evidence for ribavirin-induced viral mutagenesis. Antivir. Ther. 8, 535-540 (2003).
84. Ward CL, Dev A, Rigby S et al.: Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. J. Viral Hep. 15, 571-577 (2008).
85. Hofmann WP, Polta A, Herrmann E et al.: Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 132, 921-930 (2007).
86. Lutchman G, Danehower S, Song BC et al.: Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132, 1757-1766 (2007).
87. Donlin MJ, Cannon NA, Yao E et al.: Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J. Virol. 81, 8211-8224 (2007).
88. Campo DS, Dimitrova Z, Mitchell RJ, Lara J, Khudyakov Y: Coordinated evolution of the hepatitis C virus. Proc. Natl Acad. Sci. USA 105, 9685-9690 (2008).
89. Aurora R, Donlin MJ, Cannon NA, Tavis JE: Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J. Clin. Invest. 119, 225-236 (2009).
90. Webster DP, Klenerman P, Collier J, Jeffery KJ: Development of novel treatments for hepatitis C. Lancet Infect. Dis. 9, 108-117 (2009).
91. Trozzi C, Bartholomew L, Ceccacci A et al.: In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77(6), 3669-3679 (2003).
92. Thompson A, Patel K, Tillman H, McHutchison JG: Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J. Hepatol. 50, 184-194 (2009). ■■ Most updated review on new specifically targeted antiviral therapy for HCV compounds for the treatment of chronic hepatitis C.
93. Holland-Staley CA, Kovari LC, Golenberg EM, Pobursky KJ, Mayers DL: Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch. Virol. 147, 1385-1406 (2002).
94. Vallet S, Gouriou S, Nousbaum J, Legrand-Quillien MC, Goudeau A, Picard B: Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J. Med. Virol. 75, 528-537 (2005).
95. López-Labrador FX, Moya A, Gonzalez-Candelas F: Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir. Ther. 13, 481-494 (2008).
96. Bartels DJ, Zhou Y, Zhang EZ et al.: Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3/4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198, 800-807 (2008).
97. Kuntzen T, Timm J, Berical A et al.: Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naive patients. Hepatology 48, 1769-1778 (2008).
98. Gaudieri S, Rauch A, Pfafferott K et al.: Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49, 1069-1082 (2009).
99. Meylan E, Curran J, Hofmann K et al.: Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005).
100. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ: Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl Acad. Sci. USA 102, 17717-17722 (2005).
101. Kawai T, Takahashi K, Sato S et al.: IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981-988 (2005).
102. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB: VISA is an adapter protein required for virus-triggered IFN-b signaling. Mol. Cell 19, 727-740 (2005).
103. Foy E, Li K, Sumpter R Jr et al.: Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA 102, 2986-2991 (2005).
104. Dansako H, Ikeda M, Ariumi Y, Wakita T, Kato N: Double-stranded RNA-induced interferon-β and inflammatory cytokine production modulated by hepatitis C virus serine proteases derived from patients with hepatic diseases. Arch. Virol. 154(5), 801-810 (2009).
105. Gale M, Foy EM: Evasion of intracellular host defence by hepatitis C virus. Nature 436, 939-945 (2005).
106. Weiner AJ, Geysen HM, Christopherson C et al.: Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl Acad. Sci. USA 89, 3468-3472 (1992).
107. Kato N, Ootsuyama Y, Sekiya H et al.: Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J. Virol. 68, 4776-4784 (1994).
108. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC: Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27, 223-227 (1998).
109. Farci P, Shimoda A, Coiana A et al.: The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339-344 (2000).
110. Farci P, Quinti I, Farci S et al.: Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc. Natl Acad. Sci. USA 103, 8475-8480 (2006).
111. von Hahn T, Chun Yoon J, Alter H et al.: Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132, 667-678 (2007).
112. Zhang P, Zhong L, Struble EB et al.: Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl Acad. Sci. USA 106, 7537-7541 (2009).
113. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl Acad. Sci. USA 96, 5692-5697 (1999).
114. Lechner F, Wong DK, Dunbar PR et al.: Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191, 1499-1512 (2000).
115. + response in patients with chronic hepatitis C. J. Med. Virol. 72, 575-585 (2004).
116. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8, 379-385 (2002).
117. Chang KM, Rehermann B, McHutchison JG et al.: Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100, 2376-2385 (1997).
118. + T cell immunity: HCV evolution, from chimpanzees to man. J. Exp. Med. 201, 1709-1714 (2005). ■■ Very detailed compilation and discussion of published data on HCV escape from the cellular immune response, including description of models for mutational escape and the evolution of HCV epitopes during infection.
119. Cox AL, Mosbruger T, Mao Q et al.: Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201, 1741-1752 (2005).
120. Laskus T, Wilkinson J, Gallegos-Orozco JF et al.: Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 127, 764-776 (2004).
121. Curran R, Jameson CL, Craggs JK et al.: Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J. Gen. Virol. 83, 11-23 (2002).
122. Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M et al.: Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. Hepatology 29, 897-903 (1999).
123. Brambilla S, Bellati G, Asti M et al.: Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology 27, 1678-1686 (1998).
124. Qin H, Shire NJ, Keenan ED et al.: HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 105, 533-541 (2005).
125. Wang XH, Netski DM, Astemborski J et al.: Progression of fibrosis during chronic hepatitis C is associated with rapid viral evolution. J. Virol. 81, 6513-6522 (2007).
126. Duverlie G, Khorsi H, Castelain S et al.: Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J. Gen. Virol. 79, 1373-1381 (1998).
127. Puig-Basagoiti F, Forns X, Furcic I et al.: Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J. Gen. Virol. 86, 1067-1075 (2005).
128. Wohnsland A, Hofmann WP, Sarrazin C: Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 20, 23-38 (2007). ■■ Excellent review on the molecular virology of resistance to past, present and future antiviral treatment for HCV.
129. Cuevas JM, Torres-Puente M, Jimenez-Hernandez N et al.: Genetic variability of hepatitis C Virus before and after combined therapy of interferon plus ribavirin. PLoS ONE 3, e3058 (2008).
130. Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE: Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS ONE 3, e2123 (2008).
131. Sarrazin C, Kieffer TL, Bartels D et al.: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007).
132. Kieffer TL, Sarrazin C, Miller JS et al.: Telaprevir and PEGylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631-639 (2007).
133. Susser S, Welsch C, Wang Y et al.: Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology doi: 10.1002/hep.23192 (2009) (Epub ahead of print).
134. BioAfrica: Oxford HCV Subtyping Tool Web Interface. http://bioafrica.mrc. ac.za/rega-genotype/html/subtypinghcv.html